Our PM Albo, when not wailing about carbon emissions, a wailing that increases carbon emissions by the way, however minute, wants us all to have four vaxxes, with no end in sight. Now, apart from keeping the mega-profits flowing for Big Pharma, what will this do? Well, four jabs have not yet been scientifically investigated, which is in-itself a knock down reason for rejecting a fourth jab, even for the vaxxed. Is there proof of safety with an infinite succession of jabs? No-one knows because the studies have not been done and probably will not be, as the vaxxed are the study, contrary to all medical ethics.

Nevertheless according to a recent study published in the New England Journal of Medicine, research from a group at Weill Cornell Medicine in Qatar showed that the level of protection  against infection from Covid Omicron from natural immunity vastly outstrips that of a two-dose regimen of the available mRNA vaccines against SARS CoV-2. The study noted that while individuals maintained protection against the virus from natural immunity over 300 days after their first infection, a two-dose regimen of Pfizer’s jab quickly waned in effectiveness, dropping to -3.4 percent after six months. This indicates that one would be better protected against infection if they did not receive any Covid vaccine at all! Thus, will four jabs be any better, considering that each time one gets a jab, one is essentially playing vaccine Russian roulette with adverse effects, which might catch one in the end?

https://www.lifesitenews.com/news/new-study-finds-two-mrna-shots-provide-negative-immunity-against-covid/

“A new study has found that two doses of the abortion-tainted mRNA anti-COVID jabs can lead to a decrease in protection against the novel coronavirus compared with that gained by natural immunity.

Published in the prestigious New England Journal of Medicine, research from a group at Weill Cornell Medicine in Qatar showed that the level of protection offered against infection with the omicron variant of COVID-19 from natural immunity vastly outstrips that of a two-dose regimen of the available mRNA shots against the virus.

The June 15 study, conducted between December 2021 and February 2022 in Qatar and analyzing some 100,000 individuals, demonstrated that prior infection with COVID in those who had not received a jab garnered a 46.1 and 50.2 percent level of effective protection against further infection with omicron’s two subvariants, while vaccination with two doses of Pfizer’s mRNA shot in those who had not been previously infected induced a negative effect, resulting in a -1.1 and -4.9 percent protection level.

Those who had been infected and subsequently received two shots of the mRNA jabs, which they called “hybrid immunity,” had an effective protection against reinfection with any omicron of 40.7 percent, slightly down on that given by natural immunity alone.

The authors noted that while individuals maintained protection against the virus from natural immunity over 300 days after their first infection, a two-dose regimen of Pfizer’s jab quickly waned in effectiveness, dropping to -3.4 percent after six months, indicating that one would be more protected against infection if they did not receive any jab at all.

Moderna shot recipients fared slightly worse in the study, showing a drop in effective protection against any omicron variant after six months of vaccination to -10.3 percent after starting marginally higher than that of the Pfizer equivalent.

Administering a third dose of either Pfizer or Moderna’s shots carried a renewed immunity among those with “hybrid immunity,” but as with two doses, protection began waning quickly, with both vaccines plummeting in effectiveness by between 14 and 16 points after one month.

Just over a week after the Qatari paper was circulated, the BMJ published a study showing that both Pfizer and Moderna’s jabs were more likely to hospitalize individuals due to serious adverse events from the shots than they would protect you from serious injury with COVID.

The risk of post-vaccine injury was so great that the authors concluded that there was “no evidence of a reduction in overall mortality in the mRNA vaccine trials.”

https://www.nejm.org/doi/full/10.1056/NEJMoa2203965?query=featured_home

“Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

List of authors.

• Heba N. Altarawneh, M.D., 
• Hiam Chemaitelly, Ph.D., 
• Houssein H. Ayoub, Ph.D., 
• Patrick Tang, M.D., Ph.D., 
• Mohammad R. Hasan, Ph.D., 
• Hadi M. Yassine, Ph.D., 
• Hebah A. Al-Khatib, Ph.D., 
• Maria K. Smatti, M.Sc., 
• Peter Coyle, M.D., 
• Zaina Al-Kanaani, Ph.D., 
• Einas Al-Kuwari, M.D., 
• Andrew Jeremijenko, M.D.,  et al.

Abstract

BACKGROUND

The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) variant is unclear.

METHODS

We conducted a national, matched, test-negative, case–control study in Qatar from December 23, 2021, through February 21, 2022, to evaluate the effectiveness of vaccination with BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against symptomatic omicron infection and against severe, critical, or fatal coronavirus disease 2019 (Covid-19).

RESULTS

The effectiveness of previous infection alone against symptomatic BA.2 infection was 46.1% (95% confidence interval [CI], 39.5 to 51.9). The effectiveness of vaccination with two doses of BNT162b2 and no previous infection was negligible (−1.1%; 95% CI, −7.1 to 4.6), but nearly all persons had received their second dose more than 6 months earlier. The effectiveness of three doses of BNT162b2 and no previous infection was 52.2% (95% CI, 48.1 to 55.9). The effectiveness of previous infection and two doses of BNT162b2 was 55.1% (95% CI, 50.9 to 58.9), and the effectiveness of previous infection and three doses of BNT162b2 was 77.3% (95% CI, 72.4 to 81.4). Previous infection alone, BNT162b2 vaccination alone, and hybrid immunity all showed strong effectiveness (>70%) against severe, critical, or fatal Covid-19 due to BA.2 infection. Similar results were observed in analyses of effectiveness against BA.1 infection and of vaccination with mRNA-1273.

CONCLUSIONS

No discernable differences in protection against symptomatic BA.1 and BA.2 infection were seen with previous infection, vaccination, and hybrid immunity. Vaccination enhanced protection among persons who had had a previous infection. Hybrid immunity resulting from previous infection and recent booster vaccination conferred the strongest protection. (Funded by Weill Cornell Medicine–Qatar and others.)”